Author

J. Buesa

Observed names: J BUESA, J Buesa, J M Buesa, J. M. Buesa, J.M Buesa, J.M. Buesa, JOSÉ M. BUESA, Jose Buesa, Jose M. Buesa, José M. Buesa, José Buesa, José M Buesa, José M. Buesa, José Marí Buesa

Institutions: Hospital de Sant Pau, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Hospital Universitario Miguel Servet, Hospital Clínic de Barcelona, Hospital Universitario Reina Sofía, Hospital Universitario Son Dureta, Hospital Clínico Universitario Lozano Blesa

Observed institutions: Radboud University Nijmegen, Universitat de València, Universidad de Oviedo, Universitair Ziekenhuis Leuven, Beatson West of Scotland Cancer Centre, Hospital de Sant Pau, Institut Gustave Roussy, Erasmus MC, Aarhus University Hospital, Copenhagen University Hospital, Rigshospitalet, Hospital Clínico San Carlos, Institut d'Investigació Biomédica de Bellvitge, Hospital de Basurto, Hospital Clínico Universitario de Valencia, Marqués de Valdecilla University Hospital, Fundación Instituto Valenciano de Oncología, Institut Català d'Oncologia, Hospital Universitario Miguel Servet, Hospital Clínic de Barcelona, Royal Marsden Hospital, Hospital Universitario Reina Sofía, European Organisation for Research and Treatment of Cancer, The Christie Hospital, Hospital Universitario Son Dureta, Hospital Universitario Central de Asturias, The Christie NHS Foundation Trust, Hospital Clínico Universitario Lozano Blesa, Onkologikoa, Centro de Alta Resolución San Millán, Hospital Virgen del Camino, Hospital Universitario de León, Daniel den Hoed Kliniek, University of Birmingham, Erasmus University Rotterdam

OpenAlex ID: A5111998297

Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study

1999 · M. Van Glabbeke, A.T. van Oosterom, et al. · Journal of Clinical Oncology · 608

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

1995 · A Santoro, T Tursz, et al. · Journal of Clinical Oncology · 564

A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma

2001 · E Gortzak, A Azzarelli, et al. · European Journal of Cancer · 379

Deletions Affecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS)

2005 · Javier Martín, Andrés Poveda, et al. · Journal of Clinical Oncology · 350

PDF

Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients

1996 · Albert N. van Geel, Ugo Pastorino, et al. · Cancer · 323

PDF

Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study

2011 · Xavier García-del-Muro, Antonio López-Pousa, et al. · Journal of Clinical Oncology · 306

Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

1994 · V Bramwell, J Rouesse, et al. · Journal of Clinical Oncology · 243

Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

2000 · Jaap Verweij, Siow Ming Lee, et al. · Journal of Clinical Oncology · 171

Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC soft tissue and bone sarcoma group

1987 · H.T. Mouridsen, L. Bastholt, et al. · European Journal of Cancer and Clinical Oncology · 154

Protein Kinase C θ Is Highly Expressed in Gastrointestinal Stromal Tumors But Not in Other Mesenchymal Neoplasias

2004 · Pilar Blay, Aurora Astudillo, et al. · Clinical Cancer Research · 139

Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma group

1984 · H. M. Pinedo, V. H. C. Bramwell, et al. · Cancer · 129

High-dose DTIC in advanced soft-tissue sarcomas in the adult

1991 · J.M. Buesa, H.T. Mouridsen, et al. · Annals of Oncology · 108

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

1998 · OS Nielsen, P Dombernowsky, et al. · British Journal of Cancer · 105

PDF

Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A Phase II trial

1991 · A.J. Lacave, F.J. Barón, et al. · Annals of Oncology · 96

A phase II trial of temozolomide as a 6‐week, continuous, oral schedule in patients with advanced soft tissue sarcoma

2005 · Xavier Garcia del Muro, Antonio Lopez‐Pousa, et al. · Cancer · 94

PDF

Fine needle aspiration cytology of soft-tissue lesions.

1986 · T G Miralles, F Gosalbez, et al. · PubMed · 87

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

1999 · P.J Woll, I Judson, et al. · European Journal of Cancer · 66

Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)

1998 · J.M. Buesa, A. López-Pousa, et al. · Annals of Oncology · 64

PDF

Treatment of ifosfamide encephalopathy with intravenous thiamin.

2003 · José M Buesa, Paula García-Teijido, et al. · PubMed · 55

Determination of thiamine and its phosphorylated forms in human plasma, erythrocytes and urine by HPLC and fluorescence detection: a preliminary study on cancer patients

2004 · R. Losa, M.I. Sierra, et al. · Journal of Pharmaceutical and Biomedical Analysis · 50

Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer

1983 · Angel J. Lacave, Isabel Izarzugaza, et al. · American Journal of Clinical Oncology · 50

Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ‐C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)

2005 · A. Poveda, A. López-Pousa, et al. · Sarcoma · 37

PDF

Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection

2006 · R LOSA, M SIERRA, et al. · Journal of Chromatography B · 35

European Experience of Adjuvant Chemotherapy for Soft Tissue Sarcoma: Interim Report of a Randomized Trial of Cyvadic Versus Control

1988 · Vivien Bramwell, J. Rouessé, et al. · Springer eBooks · 31

Doxorubicin in relapsed soft tissue sarcoma: Justification of phase II evaluation of new drugs in this disease

1990 · G. Blackledge, A. van Oosterom, et al. · European Journal of Cancer and Clinical Oncology · 28

Works count: 71

Citation count: 4,644

H-index: 26

I10-index: 39